Antares pharma, inc. (ATRS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenue:
Total revenue

123,864

63,554

54,515

52,222

-

-

-

-

-

-

-

Product sales

-

-

-

-

27,533

13,195

10,957

9,137

7,630

5,773

3,506

Development revenue

-

-

-

-

8,892

7,246

4,139

7,422

4,462

2,127

-

Development revenue

-

-

-

-

-

-

-

-

-

-

2,606

Licensing revenue

-

-

-

-

7,242

3,708

849

2,141

1,220

2,856

1,595

Royalties

-

-

-

-

1,991

2,351

4,671

3,874

3,144

2,061

602

Total revenue

-

-

-

-

45,658

26,501

20,618

22,575

16,458

12,818

8,311

Cost of revenue:
Total cost of revenue

50,475

31,065

27,466

28,817

-

-

-

-

-

-

-

Cost of product sales

-

-

-

-

12,925

9,359

6,990

6,116

3,623

2,799

1,813

Cost of development revenue

-

-

-

-

6,533

1,877

2,207

3,403

3,174

1,473

-

Cost of development revenue

-

-

-

-

-

-

-

-

-

-

2,326

Total cost of revenue

-

-

-

-

19,458

11,236

9,197

9,520

6,797

4,273

4,139

Gross profit

73,389

32,489

27,049

23,405

26,200

15,264

11,421

13,055

9,661

8,545

4,171

Operating expenses:
Research and development

10,624

12,328

11,854

19,592

19,731

18,638

15,263

14,921

6,699

8,802

7,902

Selling, general and administrative

61,773

36,762

31,646

27,930

26,931

31,740

17,008

9,585

-

-

-

Total operating expenses

72,397

49,090

43,500

47,522

-

-

-

-

-

-

-

Gain on sale of assets

-

12,500

860

-

-

-

-

-

-

-

-

Sales and marketing

-

-

-

-

-

-

-

-

-

1,035

1,051

General and administrative

-

-

-

-

-

-

-

-

7,398

4,734

4,911

Total operating expenses

-

-

-

-

46,662

50,378

32,271

24,506

14,098

14,571

13,864

Operating loss

992

-4,101

-15,591

-24,117

-20,462

-35,113

-20,850

-11,451

-4,436

-6,026

-9,693

Other income (expense):
Interest income

-

-

-

-

-

76

111

63

55

30

-27

Foreign exchange gain (loss)

-

-

-

-

-

0

-8

14

-19

-

-

Interest expense

3,549

2,675

1,423

-

-

-

-

-

-

-

-633

Foreign exchange gain (loss)

-

-

-

-

-

-

-

-

-

-31

40

Other, net

-

-

-

-

-

-

-

-

-

-63

-49

Other income

530

261

271

-122

-22

-90

-59

-53

13

-64

-

Total other expense, net

-3,019

-2,414

-1,152

-122

-22

-13

43

24

48

-

-

Net loss before income taxes

-2,027

-6,515

-16,743

-24,239

-20,484

-35,126

-20,806

-11,427

-4,387

-

-

Income tax provision

-

-

-

100

175

25

-300

-

-

-

-

Total other income (expense)

-

-

-

-

-

-

-

-

-

-

597

Net loss

-2,027

-6,515

-16,743

-24,339

-20,659

-35,151

-20,506

-11,427

-4,387

-6,091

-10,290

Net loss per common share, basic and diluted

-0.01

-0.04

-0.11

-0.16

-0.14

-0.27

-0.16

-0.10

-0.05

-

-

Weighted average common shares outstanding, basic and diluted

162,574

157,407

156,054

154,992

146,594

130,549

126,897

110,185

96,994

-

-

Basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-0.07

-0.14

Basic and diluted weighted average common shares outstanding

-

-

-

-

-

-

-

-

-

83,170

73,488

Product sales [Member]
Total revenue

92,103

47,870

41,695

40,318

-

-

-

-

-

-

-

Total cost of revenue

46,267

29,094

22,317

23,909

-

-

-

-

-

-

-

Licensing and Development Revenue [Member]
Total revenue

7,529

6,753

11,171

10,401

-

-

-

-

-

-

-

Royalties [Member]
Total revenue

24,232

8,931

1,649

1,503

-

-

-

-

-

-

-

Cost of development revenue [Member]
Total cost of revenue

4,208

1,971

5,149

4,908

-

-

-

-

-

-

-